Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Acular LS approved

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Allergan expects to launch Acular LS in the third quarter. The ketorolac tromethamine 0.4% ophthalmic solution clears FDA May 30 "for the reduction of ocular pain and burning/stinging following corneal refractive surgery." The "optimized formulation" joins Allergan's Acular (ketorolac 0.5%) family "used for a range of other conditions including post-surgical inflammation, pain, photophobia and ocular itch associated with seasonal allergies
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel